Biopharma companies are increasingly outsourcing drug manufacturing to Europe, particularly Germany, to diversify supply chains amid U.S. tariff pressures and global uncertainties.

Eli Lilly is using predictive algorithms and vision AI to identify bottlenecks and inspect vials at unprecedented speeds, scaling manufacturing without new facilities.

Hong Kong has signed agreements with 22 companies, including pharmaceutical giant Pfizer, to establish or expand operations in life and health technology sectors.

The European Economic and Social Committee has adopted an opinion calling for accelerated biotechnology development in Europe to prevent falling behind global competitors.

Hong Kong government inks deals with 22 companies, including pharmaceutical giant Pfizer, to establish or expand operations in life and health technology and other strategic sectors.

Chinese biopharma companies have driven a 132% increase in innovative drug out-licensing deals totaling $56.7 billion across 44 transactions since early 2026, underscoring China's rising dominance in the global pharmaceutical sector.

The European Economic and Social Committee has issued an opinion pushing the EU to boost biotechnology through streamlined regulations, investments, and a unified ecosystem to keep pace with global rivals.

AstraZeneca announces a $15 billion investment to enhance cell therapy, radioconjugate development, and manufacturing facilities across China, supporting oncology, haematology, and autoimmune pipelines.

The European Medicines Agency has announced an online information session on April 24, 2026, to prepare stakeholders for the upcoming breakthrough medical devices pilot launching in Q2 2026.

Chinese innovative drug outbound licensing deals exceeded RMB 400 billion in Q1 2026, with record upfront payments and focus on GLP-1, ADCs, and bispecific antibodies.